Your fact-checks will appear here
Part of Earth that lies south of the equator
Early evidence shows 2025–26 flu vaccines likely cut medically attended illness and hospitalizations roughly in half in settings where the same viruses circulated as in the Southern Hemisphere (about ...
Recent surveillance and effectiveness studies show that a minority of hospitalized flu patients had been vaccinated in Southern Hemisphere analyses (15.9% vaccinated among hospitalized cases) and vacc...
Early real-world data indicate are substantially protective against severe outcomes: estimates from the and international analyses place vaccine effectiveness (VE) against influenza-associated hospita...
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
Early 2025–26 field estimates indicate the H3N2 component of this season’s vaccine is substantially protective against severe outcomes in children but only modestly protective in adults, with children...
Available reporting shows mixed evidence about how well recent vaccines protect against currently circulating influenza viruses: Southern Hemisphere 2025 interim data suggest roughly 50% reduction in ...
Public reporting from CDC and partner networks indicates there is no single fixed calendar date for a U.S. influenza vaccine effectiveness (VE) estimate for the 2025–26 season; instead CDC and its sur...
If every nuclear warhead on Earth were detonated, neither Australia nor New Zealand would be untouched — nuclear winter and global fallout would affect both — but available research rates Australia as...
Real-world effectiveness studies for the 2024–25 and early 2025 seasons generally showed moderate protection against medically attended illness and hospitalization — typically roughly 37%–63% in U.S. ...
Randomized trial data for 2025–2026 influenza vaccines are limited in the available reporting; most contemporary efficacy/effectiveness figures come from observational VE networks and Southern Hemisph...
Seasonal updates to H3N2 components of influenza vaccines are driven by coordinated global surveillance, laboratory antigenic and genetic analyses, and formal recommendations by international and nati...
The Centers for Disease Control and Prevention (CDC) does not publish a fixed calendar date for U.S.-specific influenza vaccine effectiveness (VE) estimates for a given season; instead, CDC’s four U.S...
Interim real‑world estimates for the 2025 influenza vaccine’s protection against hospitalization cluster by age: children and adolescents show strong protection in some datasets (~63%–78% and 72%–75% ...
The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) each report that H3N2 subclade K (J.2.4.1) has become widely detected but — based on current laboratory sur...
Early real‑world data indicate the 2024–2025 influenza vaccine modestly reduced risk of hospitalization overall, with estimates for H3N2‑associated hospitalization ranging from near‑null in some adult...
The 2025 influenza vaccine delivered , with stronger protection reported against influenza B and H1N1 subtypes and weaker protection against H3N2. These findings are preliminary and derived from surve...